Open Accessibility Menu
Hide

Mark A. Healy, MD

About the provider

Mark Healy, MD, MSc, provides patients with the most advanced surgical treatments. Throughout the care experience, he ensures that patients and their loved ones have as much information as possible to assist them in making decisions. Specializing in removing or treating an array of cancers, Dr. Healy is board-certified in both surgery and complex general surgical oncology.

Dr. Healy offers patients the best and most current data-driven cancer treatments while setting clear and appropriate expectations of results. He provides highly skilled surgical care to remove or treat cancers of the stomach, liver, gallbladder, bile duct, pancreas, small intestine, spleen and colon and delivers expert surgical treatment for neuroendocrine tumors, peritoneal malignancies, melanoma, soft tissue sarcomas and retroperitoneal sarcomas.

Prior to moving to the Central Coast of California, he served at the highly acclaimed Banner MD Anderson Cancer Center in Gilbert, Arizona and as an Adjunct Assistant Professor of Surgery at the University of Texas MD Anderson Cancer Center in Houston.

Dr. Healy has held teaching positions ranging from direct work with medical students, residents and fellows, to mentorship and educational advisory committees. He has been involved extensively in cancer research and has authored numerous peer-reviewed publications in medical journals.

An avid runner, Dr. Healy has participated in the Chicago Marathon several times. He also loves dogs, reading, cooking and spending as much free time as possible in the great outdoors.
Education
  • Fellowship
  • University of Texas MD Anderson Cancer Center Houston, TX
    2020
  • Residency
  • University of Michigan Health System Ann Arbor, MI
    2018
  • Medical Education
  • University of Chicago Pritzker School of Medicine Chicago, IL
    2011

Meet surgical oncologist Mark Healy, MD.

Podcast: Pancreatic Cancer

Podcast: Cáncer de Páncreas

Publications

Click on title below for details:

  • Hepatocellular Carcinoma Recurrence Risk in the Context of Emerging Therapies.

    Healy MA, Choti MA. Ann Surg Oncol. 2022 May 5. doi: 10.1245/s10434-022-11709-8. Epub ahead of print. PMID: 35513591.

    View Publication
  • High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action.

    Healy MA, Peacock O, Hu CY, Bednarski BK, Tillman MM, Messick C, Kaur H, Chang GJ. Ann Surg. 2022 Dec 1;276(6):1023-1028. doi: 10.1097/SLA.0000000000004682. Epub 2020 Dec 22. PMID: 33630474.

    View Publication
  • Comment on "A National Cancer Database Analysis of Microsatellite Instability and Pathologic Complete Response in Locally Advanced Rectal Cancer"

    You YN, Rodriguez-Bigas MA, Das P, Healy M, Chiang YJ, George T, Vilar E. Ann Surg. 2021 Aug 1;274(2):e197-e198. doi: 10.1097/SLA.0000000000003785. PMID: 31972642.

  • Screening high-risk populations for colon and rectal cancers.

    Healy MA, Thirumurthi S, You YN. J Surg Oncol. 2019 Oct;120(5):858-863. doi: 10.1002/jso.25648. Epub 2019 Jul 31. PMID: 31368175.

    View Publication
  • Surgeon Perspectives Regarding Death and Dying.

    Dillon BR, Healy MA, Lee CW, Reichstein AC, Silveira MJ, Morris AM, Suwanabol PA. J Palliat Med. 2019 Feb;22(2):132-137. doi: 10.1089/jpm.2018.0197. Epub 2018 Nov 17. PMID: 30457430.

    View Publication
  • The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program.

    Healy MA, Morris AM, Abrahamse P, Ward KC, Kato I, Veenstra CM. BMC Cancer. 2018 Apr 27;18(1):481. doi: 10.1186/s12885-018-4405-7. PMID: 29703172; PMCID: PMC5924509.

    View Publication